Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | GFER | P55789 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.57 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.57 |
| ▸ | VCP | P55072 | 1/20 | 0.57 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | PARP1 | P09874 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7330009 | 0.98 | MEN1 (0.59) | MEN1KMT2AMAPTSMN1; SMN2GFER | |
| SCHEMBL3598628 | 0.97 | MAPT (0.58) | MEN1KMT2AMAPTSMN1; SMN2GFER | |
| SCHEMBL3615155 | 0.90 | ALOX5 (0.51) | MEN1KMT2AMAPTSMN1; SMN2GFER | |
| SCHEMBL3610620 | 0.88 | ATP4A (0.49) | MEN1KMT2AMAPTSMN1; SMN2GFER | |
| SCHEMBL27768248 | 0.87 | ATP4A (0.56) | MEN1KMT2AMAPTELOVL1RAB9A | |
| SCHEMBL2380037 | 0.87 | RAB9A (0.61) | MEN1KMT2AMAPTSMN1; SMN2GFER | |
| SCHEMBL3613607 | 0.87 | LTA4H (0.59) | MEN1KMT2AMAPTSMN1; SMN2GFER | |
| SCHEMBL4330706 | 0.86 | SCD (0.70) | MEN1KMT2AMAPTSMN1; SMN2ADORA3 | |
| SCHEMBL3604799 | 0.86 | ALOX5 (0.61) | MEN1KMT2AMAPTSMN1; SMN2GFER | |
| SCHEMBL3594785 | 0.86 | MAPT (0.65) | MEN1KMT2AMAPTSMN1; SMN2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| CN-101466692-A | Thiazol-guanidine derivatives useful as a (beta) - related pathologies | ASTRAZENECA AB (SE) | 2009-06-24 | — | — | CN | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| EP-4638427-A1 | AMIDINOUREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | Université Côte d'Azur (FR) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024133857-A1 | AMIDINOUREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | UNIVERSITE COTE D'AZUR (FR) | 2024-06-27 | — | — | WO | disclosed |
| CN-111825633-B | Method for synthesizing 2-guanidyl thiazole compounds by one-pot method | 西华大学 | 2023-11-17 | — | — | CN | disclosed |
| US-11440906-B2 | Biguanide derivatives and their rearrangement products for use in the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-09-13 | — | — | US | disclosed |
| EP-3728211-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | Centre National de la Recherche Scientifique (FR) | 2020-10-28 | — | — | EP | disclosed |
| CN-111836803-A | Compounds and their use in the treatment of cancer | 国家科学研究中心 | 2020-10-27 | — | — | CN | disclosed |
| CN-111825633-A | Method for synthesizing 2-guanidino thiazole compound by one-pot method | 西华大学 | 2020-10-27 | — | — | CN | disclosed |
| US-20200308156-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2020-10-01 | — | — | US | disclosed |
| US-20060264462-A1 | Imidazolamino compounds | NATIONAL HEALTH RESEARCH INSTITUTES | 2006-11-23 | — | — | US | disclosed |
| EP-1716127-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060241140-A1 | Imidazolamino compounds | NATIONAL HEALTH RESEARCH INSTITUTES A TAIWAN CORPORATION | 2006-10-26 | — | — | US | disclosed |
| US-7109227-B2 | Imidazolamino compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-09-19 | — | — | US | disclosed |
| WO-2005082871-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2005-09-09 | — | — | WO | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| US-20040157883-A1 | Imidazolamino compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | MEN1 3257/4885KMT2A 4116/4885MAPT 2/4885 |
| US-20200308156-A1 | BIGUANIDE DERIVATIVES AND THEIR REARRANGEMENT PRODUCTS FOR USE IN THE TREATMENT OF CANCER | BCR, G6PD, BRAF | MEN1 1146/4885KMT2A 3118/4885MAPT 4792/4885 |
| US-20040157883-A1 | Imidazolamino compounds | CA2, ASIC3, CNR2 | MEN1 217/4885KMT2A 1010/4885MAPT 4173/4885 |
| US-11440906-B2 | Biguanide derivatives and their rearrangement products for use in the treatment of cancer | BCR, G6PD, BRAF | MEN1 1146/4885KMT2A 3118/4885MAPT 4792/4885 |
| US-20060264462-A1 | Imidazolamino compounds | CA2, ASIC3, CNR2 | MEN1 217/4885KMT2A 1010/4885MAPT 4173/4885 |
| US-20060241140-A1 | Imidazolamino compounds | CA2, ASIC3, CNR2 | MEN1 217/4885KMT2A 1010/4885MAPT 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.